ReEmerge
Neuromodulation therapy for traumatic brain injury recovery.
The founders
NS
CB
JB
JH
The company
ReEmerge is developing Cognitive Network Restoration Therapy (CNRT), a neuromodulation platform that targets neural networks in the central thalamus to treat chronic cognitive impairment after brain injury. The aim is to restore function to underperforming circuits, starting with patients with moderate-to-severe traumatic brain injury.
The company launched from stealth on 15 September 2026 with an oversubscribed $37 million Series A co-led by U.S. Venture Partners and Santé. It says the capital will fund an upcoming clinical study, technology development and regulatory work.
The technology comes from decades of research by co-founder Dr Nicholas Schiff, Professor of Neuroscience at Weill Cornell Medicine, and colleagues, and ReEmerge holds an exclusive licence from Cornell University. The company is led by Chief Executive Officer Todd Langevin.
The scientific co-founders are Schiff, Christopher Butson, previously at Cleveland Clinic, Jonathan Baker, previously at NYU Winthrop, and Jaimie Henderson.
Who else is building in this space
Companies working on the same thing, at every stage.
Scale-up
Medical technology company pioneering a new class of electrical medicine called neuroperipheral therapy
Scale-up
A range of medical devices
Scale-up
Medical device company that develops and commercializes neurostimulation devices to treat neurological diseases
Neurotechnology enabling recovery after spinal cord injury
Pharyngeal electrical stimulation therapy restoring neurological swallowing control
High-resolution graphene interfaces for precision neurology.
Thousands more founded every month.
Dealroom tracks new companies as they appear — founders, funding and signals, over the API or in the platform.